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Abstract
Rhomboid proteases, first discovered in Drosophila, are intramembrane serine proteases. Members of the rhomboid protein 
family that are catalytically deficient are known as inactive rhomboids (iRhoms). iRhoms have been implicated in wound 
healing, cancer, and neurological disorders such as Alzheimer’s and Parkinson’s diseases, inflammation, and skin diseases. 
The past decade of mouse research has shed new light on two key protein domains of iRhoms—the cytosolic N-terminal 
domain and the transmembrane dormant peptidase domain—suggesting new ways to target multiple intracellular signaling 
pathways. This review focuses on recent advances in uncovering the unique functions of iRhom protein domains in normal 
growth and development, growth factor signaling, and inflammation, with a perspective on future therapeutic opportunities.
The rhomboid proteins: rhomboid proteases 
and rhomboid pseudoproteases
Rhomboid proteins are a highly conserved superfamily of 
polytopic membrane proteins (Urban and Dickey 2011). 
Rhomboid proteins can be broadly classified into active 
(Lastun et al. 2016) and inactive enzymes (Freeman 2014), 
also called pseudoproteases or iRhoms. Active rhomboid 
proteins, first discovered in Drosophila as key regulators 
of epidermal growth factor receptor (EGFR) signaling, 
are intramembrane serine proteases that hydrolyze pep-
tide bonds within the lipid bilayer (Lemberg et al. 2005). 
Catalysis is achieved by a histidine-serine dyad, which is 
submerged 10 Å below the cell membrane surface (Fig. 1A). 
Conversely, iRhoms lack a catalytic serine residue and hence 
do not retain any enzymatic protease activity (Fig. 1B). Nev-
ertheless, the iRhoms RHBDF1 and RHBDF2 have been 
implicated in neurological disorders including Alzheimer’s 
and Parkinson’s diseases, as well as in cancer, inflamma-
tion, and skin diseases (Jager et al. 2014; Raj et al. 2018; 
Hosur et al. 2014; Hosur et al. 2018; Yan et al. 2008; Zhou 
et al. 2014; Zou et al. 2009; Blaydon et al. 2012; Young 
2019). Nearly a decade of research in mice has emphasized 
an essential role for these two proteins in normal functioning 
of the brain, heart, skin, eye, bone, adipose tissue, and the 
immune system. In line with the role of active rhomboids in 
EGFR signaling, findings from mouse models demonstrate 
that iRhoms are also essential regulators of EGFR signaling. 
While loss-of-function (LOF) mutations in Rhbdf1, Rhbdf2, 
or both significantly suppress stimulated secretion of EGFR 
ligands, gain-of-function (GOF) mutations in either Rhbdf1 
or Rhbdf2 stimulate enhanced EGFR ligand secretion. 
iRhoms consist of a long cytosolic N-terminal domain, a 
conserved cysteine-rich iRhom homology domain (IRHD), 
a six transmembrane (TM helices 1–6) core (Fig. 1B), and an 
additional TM segment (TM helix 7). The six TM core har-
bors the dormant peptidase domain (TM helices 2–6), which 
has an alanine residue (instead of serine) in the enzyme core. 
In this review, we describe how insights from mouse mod-
els carrying either spontaneous mutations or CRISPR/Cas9-
induced gene modifications in Rhbdf1 and Rhbdf2 have been 
crucial in identifying their physiological targets, in defining 
the unique roles of iRhom protein domains in development 
and disease, and in nominating possible novel therapeutic 
opportunities targeting iRhoms.
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Overlapping and discrete functions 
of RHBDF1 and RHBDF2 in regulating EGFR 
signaling
Evidence for shared targets and function
Homozygous Rhbdf1 knockout mice (KO) exhibit mul-
tiorgan pathologies, including brain hemorrhage, cardiac 
fibrosis, and lower body weight compared with heterozy-
gous littermates, and die within two weeks after birth 
(Christova et al. 2013; Hosur et al. 2020) (Fig. 2A). Con-
versely, Rhbdf2-null mice are healthy and fertile and do 
not present with growth retardation or brain and heart 
defects (Hosur et al. 2014; Adrain et al. 2012; McIlwain 
et al. 2012; Siggs et al. 2012) (Fig. 2B). Nevertheless, a 
combined absence of RHBDF1 and RHBDF2 results in a 
more severe phenotype than either Rhbdf1 or Rhbdf2 KO, 
as evidenced by sub-viability and eyelids open at birth 
(EOB) observed in  Rhbdf1:Rhbdf2 double KO mice 
(Fig. 2C) (Hosur et al. 2020). This phenotype, together 
with the multiorgan pathology exhibited by Rhbdf1-null 
mice, suggests that (1) RHBDF1 and RHBDF2 have over-
lapping functions, as the presence of RHBDF2 reverses 
sub-viability and the EOB phenotype in Rhbdf1 KO mice 
(Hosur et al. 2020), and (2) RHBDF1 and RHBDF2 share 
some physiological functions and targets.
Evidence for distinct targets and function
Studies of Rhbdf1 and Rhbdf2 GOF mutant mice (Fig. 2D, 
E)—Rhbdf1viable (Hosur et al. 2020), curly bare (Rhbdf2cub), 
uncovered (Rhbdf2uncv), and CRISPR/Cas9-mediated geneti-
cally engineered mouse model of tylosis with esophageal 
cancer (Rhbdf2TOC)—suggest that RHBDF1 and RHBDF2 
have distinct functions, and thereby distinct physiologi-
cal targets. Rhbdf1viable mice, which are generated using 
CRISPR/Cas9-mediated excision of exons 2 and 3 of 
the Rhbdf1 gene, are healthy, viable, and fertile. Despite 
lacking the exons containing the transcription start site 
(ATG), the mutant viable transcript produces an N-termi-
nal-truncated RHBDF1 protein (ΔN1–151) using the next 
in-frame ATG, which is in exon 4. While most Rhbdf1-
null mice die by postnatal day 14, no abnormalities are 
observed in Rhbdf1viable mice (Fig. 2D), suggesting that 
the viable mutation rescues the severe multiorgan patholo-
gies observed in RHBDF1-deficient mice. Additionally, 
the viable allele rescues the sub-viability of Rhbdf1:Rhbdf2 
double KO mice (Fig. 2F) and induces enhanced stimulated 
secretion of EGFR ligands in vitro, suggesting that viable 
is a gain-of-function mutation. Consistent with the obser-
vations that mutations in the N-terminus of Rhbdf1 result 
in GOF mutants, either loss of the N-terminus (loss of 
amino acids 1–268 [ΔN1–268],  Rhbdf2cub  mutation) 
(Hosur et al. 2014; Siggs et al. 2014), or missense muta-
tions (p.P159L, Rhbdf2TOC mutation) (Hosur et al. 2017) 
in the N-terminus of Rhbdf2, yields GOF mutant mice. 
Each of these two mutations induces, through enhanced 
amphiregulin (AREG) secretion, accelerated wound heal-
ing and a loss-of-hair phenotype (Fig. 2E). In addition, 
uncovered, a recessive mouse mutation (Rhbdf2uncv) results 
from a spontaneous loss of 309  bp in the N-terminus 
of Rhbdf2 (ΔN118–191) (Li et al. 1999). Like Rhbdf2cub 
and Rhbdf2TOC, Rhbdf2uncv mice exhibit a loss-of-hair phe-
notype. Loss of RHBDF2 does not affect skin architecture or 
hair development, indicating that Rhbdf2uncv is a GOF muta-
tion and that mutations in the N-terminus of Rhbdf2 facili-
tate transmembrane domain (TMD)-mediated enhanced 
secretion of EGFR ligands. Interestingly, whereas Rhbdf2 
GOF (Rhbdf2cub, Rhbdf2TOC, and Rhbdf2uncv) mutant mice 
exhibit a loss-of-hair phenotype through enhanced secretion 
of AREG (Christova et al. 2013; Siggs et al. 2012), Rhbdf1 
GOF (Rhbdf1viable and Rhbdf1viable2) mutant mice have a nor-
mal hair coat (Hosur et al. 2020), suggesting that RHBDF1 
Fig. 1  Schematic topological models of the Rhomboid proteins. The 
rhomboid proteins: both active and inactive rhomboid proteins con-
tain a cytosolic N-terminal domain (N), a six or seven transmembrane 
domain (TMD), an extracellular loop or iRhom homology domain 
(IRHD) (in the case of iRhoms) in between transmembrane helices 
(TMH) 1 and 2, and a C-terminal domain (C). A In the case of active 
rhomboids, the catalytic dyad is formed by the highly conserved ser-
ine and histidine residues in transmembrane helices 4 and 6, respec-
tively. B iRhoms lack the serine residue in transmembrane helix 4 
and hence lack serine protease activity. The E. coli rhomboid protease 
GlpG crystal structure shows the catalytic dyad residues serine and 
histidine (left) in transmembrane helices 4 and 6. Catalytic serine 
has been replaced with alanine in iRhoms in transmembrane helix 4 
(right)
417Inactive rhomboid proteins RHBDF1 and RHBDF2 (iRhoms): a decade of research in murine models 
1 3
Fig. 2  Loss-of-function 
(LOF) and gain-of-function 
(GOF) mouse models of 
iRhoms. A Rhbdf1-null mice 
exhibit brain hemorrhage, 
cardiac fibrosis, and lower 
body weight than control lit-
termates. B Rhbdf2-null mice 
are healthy and fertile and do 
not show brain, heart, or growth 
defects. C A combined loss 
of Rhbdf1 and Rhbdf2 results in 
sub-viability and eyelids open at 
birth (EOB) phenotype. D GOF 
mutations in the Rhbdf1 gene, 
such as viable (v) 1, viable 
2, and viable 3, produce an 
N-terminal-truncated protein 
to rescue the overt phenotype 
observed in the Rhbdf1-null 
mice in panel A. E GOF 
mutations in the Rhbdf2 gene, 
such as Rhbdf2cub, Rhbdf2uncv, 
and Rhbdf2P159L, exhibit a 
loss-of-hair phenotype through 
enhanced secretion of EGFR 
ligand AREG via the TMD. F 
The Rhbdf1v/v allele reverses 
sub-viability of Rhbdf1:Rhbdf2 
double KO mice in panel C. 
Rhbdf1v/vRhbdf2−/− mice show 
an EOB phenotype and develop 
a wavy hair coat; however, no 
cardiac or brain abnormalities 
are observed in Rhbdf1v/vRh-
bdf2−/− double mutant mice. 
Rectangles indicate deleted 
regions
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In vitro studies in mouse embryonic fibroblasts reveal that 
RHBDF1 deficiency suppresses the stimulated secretion 
of EGFR ligands, including AREG, heparin-binding EGF 
(HB-EGF), and transforming growth factor-alpha (TGFα) 
(Hosur et al. 2020; Li et al. 2015). Additionally, short hair-
pin RNA (shRNA) or small interfering RNA (siRNA)-
mediated silencing of RHBDF1 in various human breast 
cancer cell lines and a human squamous cancer cell line 
significantly inhibited TGFα-mediated EGFR signaling and, 
further, showed anti-cancer effects by inhibiting cell prolif-
eration and invasion and, ultimately, tumor growth in vivo 
(Yan et al. 2008; Zhou et al. 2014; Zou et al. 2009). These 
studies suggest that RHBDF1 might regulate EGFR signal-
ing through secretion of multiple EGFR ligands, and that 
RHBDF2 does not compensate for the loss of RHBDF1-
mediated signaling underlying the multiorgan pathologies 
observed in Rhbdf1 KO mice.
Despite the clear biological importance of RHBDF1, the 
precise molecular mechanisms and the physiological targets 
of RHBDF1 underlying the multiorgan pathology and anti-
cancer effects resulting from RHBDF1 deficiency remain to 
be investigated. It is unlikely that the pathology observed 
in Rhbdf1-null mice is mediated solely through AREG, HB-
EGF, and/or TGFα, as mice lacking either AREG or TGFα 
are healthy and fertile (Luetteke et al. 1999; Luetteke et al. 
1993; Mann et al. 1993). However, RHBDF1 likely regulates 
the secretion of more than one EGFR ligand. In particular, 
the cardiac fibrosis observed in Rhbdf1-null mice resem-
bles the heart enlargement displayed by Hbegf-null mice 
(Iwamoto et al. 2003), and the eyelids open at birth (EOB) 
observed in Rhbdf1:Rhbdf2 double KO mice resembles the 
EOB phenotype displayed by Hbegf and Tgfa double null 
mice (Mine et al. 2005). Together, these observations sug-
gest that HB-EGF and TGFα could be the physiological tar-
gets of RHBDF1.
If defects in EGFR signaling alone underlie the multior-
gan pathology observed in Rhbdf1-null mice, it is likely that 
RHBDF2 compensates for the loss of RHDBF1 during early 
development through secretion of TGFα, particularly during 
eyelid development. This is because, although Rhbdf1-null 
mice exhibit multiorgan pathology (Hosur et al. 2020), they 
do not exhibit the in utero lethality, EOB phenotype, and epi-
dermal defects observed in Egfr-null mice (Miettinen et al. 
1999; Sibilia and Wagner 1995). Furthermore, mice lack-
ing both HB-EGF and TGFα show a highly penetrant EOB 
phenotype that is not observed in Rhbdf1-null mice, sug-
gesting that RHBDF2 compensates for the loss of RHBDF1 
only during early development to facilitate EGFR signaling, 
including during eyelid development, through secretion of 
TGFα.
RHBDF2
In vitro, loss of RHBDF2 has been shown to result in sig-
nificantly reduced stimulated secretion of EGFR ligands, 
including AREG, HB-EGF, and TGFα (Siggs et al. 2014; 
Maretzky et al. 2013). In vivo studies in mice suggest that 
AREG is a bona fide physiological target of RHBDF2. In 
humans, dominant mutations in RHBDF2 cause tylosis with 
esophageal cancer (TOC) syndrome through a hyperactive 
EGFR signaling pathway. Using spontaneous (Rhbdf2cub/cub 
and Rhbdf2cub/cub Areg−/−) (Hosur et al. 2014) and CRISPR/
Cas9 (Rhbdf2TOC) (Hosur et al. 2017) genetically engineered 
mouse models, we have shown that dominant mutations in 
RHBDF2 induce a hyperactive EGFR phenotype through 
enhanced secretion of AREG, and that genetic deletion 
of Areg in Rhbdf2cub/cub mice or Rhbdf2TOC mice prevents 
TOC. Further, shRNA-mediated silencing of Areg inhibits 
the hyperactive EGFR signaling phenotype in Rhbdf2cub/cub 
embryonic fibroblasts (Hosur et al. 2014). Together, these 
studies suggest that AREG is a physiological target of 
RHBDF2.
Cytosolic N‑terminus and TM helix 1 
of RHBDF1 are dispensable for normal 
growth and development
The Rhbdf1viable mutation generates an N-terminal-truncated 
RHBDF1 protein (ΔN1–151) (Fig. 3A, B), which rescues 
the severe multiorgan pathologies observed in RHBDF1-
deficient mice (Fig. 2D). Notably, even in the absence of the 
N-terminal domain, the mutant Rhbdf1v/v transcript gener-
ated by the Rhbdf1v/v mutation induces enhanced secretion 
of EGFR ligands, suggesting that the IRHD and the TMD of 
RHBDF1 are sufficient to mediate EGFR signaling.
Rhbdf1viable2 mice, which were first generated by Li X. 
et al. are Rhbdf1 homozygous mutant mice lacking exons 
4–11 in the  Rhbdf1  gene (Li et  al. 2015). The result-
ing Rhbdf1 mutant transcripts yield two variant proteins 
(~ 32 and ~ 29 kDa) that each lack the entire N-terminus, 
the TM helix 1, and the majority of the IRHD (Fig. 3C). 
Like Rhbdf1viable mice, Rhbdf1viable2 mice are healthy and 
fertile and do not exhibit the cardiac, brain, or growth defects 
observed in Rhbdf1-null mice. Rhbdf1viable2 mice are referred 
to by this name because of the phenotypic similarity to 
Rhbdf1viable mice. Since the N-terminus, the TM helix 1, 
and the majority of the IRHD are lost in Rhbdf1viable2 mice, 
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and these mice remain healthy and fertile, we reasoned that 
the entire N-terminus, the IRHD, and the TM helix 1 might 
be dispensable. Instead, we found that either of the two vari-
ant proteins, each consisting solely of TM helices 2–7, is 
adequate to rescue the Rhbdf1-null phenotype (Hosur et al. 
2020). This result explains the healthy and fertile pheno-
types observed in Rhbdf1viable and Rhbdf1viable2 mice, with 
no brain, heart, or body weight defects.
The Rhbdf1viable2 homozygous mutant mice reported by 
Li et al. were generated using the KO-first gene disruption 
strategy. Nevertheless, the Rhbdf1viable2 mutant mice are 
not homozygous-null because the Rhbdf1viable2 mutant tran-
script generates truncated proteins through an alternative 
promoter usage and through exon skipping. Interestingly, 
DNA sequencing revealed that the Rhbdf1viable2 allele retains 
the En2 splice acceptor sequence from the cassette used to 
generate the KO-first allele, resulting in novel mutant tran-
scripts lacking the N-terminus, TM helix 1, and the majority 
of the IRHD (72%) (Hosur et al. 2020). Thus, to further vali-
date if the N-terminus, TM helix 1, and the majority of the 
IRHD are dispensable, we generated Rhbdf1viable3 mice using 
CRISPR/Cas9-mediated gene editing in C57BL/6 J mice. 
We excised exons 4 through 13 in the Rhbdf1 gene, resulting 
in mice lacking the N-terminus, the first TM helix 1, and 
72% of the IRHD, but that retain TM helices 2–7 that harbor 
the dormant peptidase domain (Fig. 3D). We refer to these 
mice as viable 3 (Rhbdf1v3) (unpublished observations). We 
observed that homozygous-viable 3 (Rhbdf1v3/v3) mice did 
not display any gross deformities of major organs, which is 
consistent with both the Rhbdf1viable (Rhbdf1ΔN1-151) mice 
and Rhbdf1viable2 (lacking exons 4–11) mice, and in contrast 
to the Rhbdf1null/null mice that show multiorgan pathology 
and die within two to three weeks. Collectively, these stud-
ies suggest that the cytosolic N-terminus, TM helix 1, and 
possibly the IRHD of RHBDF1 are dispensable for normal 
growth and development.
Cytosolic N‑terminus and TM helix 1 
of RHBDF2 regulate inflammatory signaling 
through TNFα secretion
While the N-terminus and the TM helix 1 of iRhoms are 
dispensable for normal growth and development, they never-
theless play an important role in RHBDF2-mediated inflam-
matory signaling. In mice, loss of RHBDF2 significantly 
Fig. 3  Domains of RHBDF1 
gain-of-function proteins. A A 
schematic of the full-length 
mouse RHBDF1 protein show-
ing the cytosolic N-terminus 
domain, IRHD, transmembrane 
helices, and the peptidase 
domain. B A schematic of the 
mouse RHBDF1 viable pro-
tein showing the loss of 151 
amino acids in the N-terminal 
domain. C A schematic of the 
mouse RHBDF1 viable2 pro-
tein showing the complete loss 
of the cytosolic N-terminal 
domain and the partial loss of 
the IRHD (Targeted KO-first 
allele). D A schematic of the 
mouse RHBDF1 viable3 pro-
tein showing the complete loss 
of the N-terminal domain and 
the partial loss of the IRHD. 
Notably, all three mutant 
proteins, viable, viable2, 
and viable3 retain the dormant 
peptidase domain (CRISPR/
Cas9 generated allele)
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reduces regulated secretion of TNFα following stimulation 
with bacterial endotoxin lipopolysaccharide (LPS) (Hosur 
et al. 2014; Adrain et al. 2012; McIlwain et al. 2012; Siggs 
et al. 2012). Particularly, the N-terminus seems to be essen-
tial for TNFα secretion, because Rhbdf2cub mice, which lack 
the N-terminal domain similarly to Rhbdf2-null mice, show 
significantly reduced TNFα secretion upon stimulation with 
LPS, demonstrating that the N-terminal domain is essen-
tial for TNFα secretion (Hosur et al. 2014). Concordantly, 
Cavadas et al. and Grieve et al. found that phosphoryla-
tion of RHBDF2 at the N-terminus is essential for TNFα 
secretion (Cavadas et al. 2017; Grieve, et al. 2017); upon 
stimulation with LPS, RHBDF2 serine phosphorylation and 
binding to 14–3–3 proteins was observed in primary mac-
rophages. Additionally, in Rhbdf2 KO macrophages, LPS-
induced TNFα secretion was rescued by RHBDF2, but not 
by N-terminal-truncated RHBDF2 lacking phosphorylation 
sites (58–361 aa) (Fig. 4A), suggesting that RHBDF2 phos-
phorylation and binding to 14–3–3 proteins controls TNFα 
release in macrophages. In addition to binding of 14–3–3 
proteins, FRMD8 has been shown to be a binding partner for 
RHBDF2. Künzel et al. and Oikonomidi et al. suggest that 
the N-terminus of RHBDF2 forms a tripartite complex with 
FRMD8 and ADAM17, a metalloprotease essential for ecto-
domain shedding of TNFα, to facilitate inflammatory sign-
aling through stimulated secretion of TNFα (Künzel et al. 
2018; Oikonomidi et al. 2018). The authors showed that 
stimulation of Frmd8 KO macrophages with LPS resulted 
in reduced secretion of TNFα, suggesting that FRMD8-
RHBDF2 interaction is necessary for TNFα secretion.
It has been suggested that the TM helix 1 of RHBDF2 
is also essential for TNFα secretion in macrophages (Li 
Fig. 4  RHBDF2 binding partners and iRhoms macrophage 
expression. A  A schematic of the full-length mouse RHBDF2 
protein showing the 14–3-3 and FERM Domain Containing 8 
(FRMD8) binding sites in the cytosolic N-terminal domain and 
the  sinecure  mutation I387F in transmembrane helix 1. B  Vio-
lin plots showing expression of various mouse and human genes 
in macrophages. In both mouse (left panel) and human (right 
panel) macrophages,  Rhbdf1,  Rhbdf2,  Tnfa, and  Adam17  are 
expressed.  Cd19  and  Cd3g  serve as negative markers, 
whereas Cd14 and Fcgr1 serve as positive controls, in macrophages
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et al. 2017). Like Rhbdf2-null mice, mice homozygous for 
the sinecure (sin) mutation, a recessive mutation in the 
Rhbdf2 gene, are viable and fertile (Siggs et al. 2012). The 
Beutler laboratory identified sinecure during a forward 
genetic screen of mice for regulators of Toll-like recep-
tor (TLR)-induced TNFα secretion. A single nonsynony-
mous mutation (A to T) in Rhbdf2 results in conversion 
of isoleucine to phenylalanine at amino acid 387 (I387F) 
(Fig.  4A). Non-complementation studies validated 
that sinecure is a mutation at the Rhbdf2 locus, as com-
pound mutant Rhbdf2sin/null mice and Rhbdf2sin/sin Rhbdf2-
null mice showed similar reductions in TNFα secretion 
following stimulation with LPS. TNFα secretion was not 
completely blocked, suggesting that constitutive secretion 
of TNFα is not affected by RHBDF2 deficiency. These 
data suggest that TM helix 1 of RHBDF2 is essential for 
stimulated secretion of TNFα.
Interestingly, the binding partners for the N-terminus 
of RHBDF2—14–3–3 proteins and FRMD8—seem to be 
dispensable for RHBDF1-mediated growth factor sign-
aling. We recently generated Ywhaq (14–3–3 theta) KO 
mice and observed that, compared with heterozygous-
null mice (Ywhaq±), homozygous-null mice (Ywhaq−/−) 
showed reduced TNFα secretion following stimulation 
with LPS. However, Ywhaq-null mice exhibit normal 
body weight, no postnatal lethality, nor any brain or heart 
defects, as observed in Rhbdf1 KO mice. This suggests 
that YWHAQ could be a binding partner for RHBDF2 
and that it might be essential for RHBDF2-mediated 
stimulated secretion of TNFα, but not for RHBDF1-
mediated growth factor signaling (unpublished observa-
tions). In line with these findings, FRMD8 also seems 
to be essential for TNFα secretion, but not for growth 
factor signaling. Specifically, we generated Frmd8 KO 
mice and observed that, compared with heterozygous-
null mice (Frmd8±), homozygous-null mice (Frmd8−/−) 
showed significantly reduced TNFα secretion following 
stimulation with LPS, in accordance with the observa-
tions of Künzel et al. and Oikonomidi et al. However, 
Frmd8 KO mice do not phenocopy Rhbdf1 KO mice in 
terms of lower body weight, postnatal lethality, or brain 
and heart defects (unpublished observations). This sug-
gests that FRMD8 could also be a binding partner for 
RHBDF2 and might be essential for RHBDF2-mediated 
stimulated secretion of TNFα, but not for RHBDF1. More 
importantly, RHBDF2-mediated stimulated secretion of 
TNFα suggests high specificity of RHBDF2 for TNFα. 
Even though RHBDF1 is expressed in both mouse and 
human macrophages (Fig. 4B), it does not compensate 
for the loss of RHBDF2 in regulating stimulated secre-
tion of TNFα, suggesting that TNFα could be a specific 
target of RHBDF2.
The dormant peptidase domain of iRhoms 
(TM helices 2–6)
Peptidase domain of RHBDF1 is sufficient for normal 
growth and development. In an in vivo screen in mice, we 
identified the minimal protein domain required for normal 
growth and development—the transmembrane peptidase 
domain of RHBDF1. The healthy and fertile phenotypes 
of Rhbdf1viable (ΔN1–151), Rhbdf1viable2, Rhbdf1viable3, and 
Rhbdf1viable Rhbdf2−/− mice (Hosur et al. 2020) (Fig. 2D, 
F), with no defects in the brain, heart, or in body weight, 
surprisingly suggest that RHBDF2 and the N-terminus, the 
IRHD, and the first TM helix of RHBDF1 are dispensable 
for normal growth and development (Hosur et al. 2020). 
However, TM helices 2–6, which harbor the dormant 
peptidase domain of RHBDF1, are adequate and essential 
for survival and normal growth and development.
Peptidase domain of RHBDF2 facilitates AREG secre-
tion. The Rhbdf2cub spontaneous mouse mutation results 
from a ~ 12.5 Kb deletion in the Rhbdf2 gene, leading to 
the loss of exons 2 through 6. Nevertheless, the Rhbdf-
2cub mutant transcript generates an N-terminal-truncated 
protein using an in-frame ATG in exon 8 resulting in loss-
of-hair and rapid wound healing phenotypes. We previ-
ously showed that the N-terminal-truncated transcript is 
sufficient to induce AREG secretion, leading to a hyper-
active EGFR phenotype. Furthermore, using site-directed 
mutagenesis, we showed that mutating residues in TM 
helices 2, 4, and 6, which harbor the dormant peptidase 
domain, prevents AREG secretion, suggesting that the dor-
mant peptidase domain of RHBDF2 is sufficient to facili-
tate AREG secretion, and that the N-terminal domain is 
dispensable for mediating the hyperactive EGFR pheno-
type observed in Rhbdf2cub mice (Hosur et al. 2014).
Highly conserved amino acid residues 
in the dormant peptidase domain of iRhoms
As noted above, the dormant peptidase domain of 
RHBDF2 is sufficient to induce accelerated wound heal-
ing in mice through enhanced secretion of AREG (Hosur 
et al. 2014). Furthermore, the survival of Rhbdf1viable2 
and Rhbdf1viable3 mice indicates that the dormant pepti-
dase domain is sufficient for survival. Nevertheless, the 
underlying molecular mechanisms are unclear. Here, we 
perform new sequence analysis of key amino acid resi-
dues in the peptidase domain of the rhomboid family using 
HMM Logos, a widely used tool for visualization of pro-
tein families, and uncover highly conserved amino acid 
residues in TM helices 2, 3, 4 and 6. We thus propose 
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that these amino acids could be critical for RHBDF1- and 
RHBDF2-mediated EGFR signaling (Fig. 5A). We fur-
ther propose that the dormant peptidase domain could also 
account for differences in substrate specificity of RHBDF1 
and RHBDF2. For instance, even though both Rhbdf1 and 
Rhbdf2 are expressed in keratinocytes (Fig. 5B), RHBDF2, 
but not RHBDF1, selectively induces accelerated wound 
healing in mice through enhanced AREG secretion. There-
fore, RHBDF1 and RHBDF2 have high specificity toward 
target proteins, which might be conferred by the peptidase 
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domain. In addition, RHBDF2 shows high specificity for 
TNFα (Hosur et al. 2014; Adrain et al. 2012; McIlwain 
et al. 2012; Siggs et al. 2012). Despite significant sequence 
homology, there are several amino acids, particularly in 
TM helices 5 and 6, that are dissimilar in both humans and 
mice between RHBDF1 and RHBDF2 (Fig. 5C). Previ-
ously, it has been suggested that amino acid residues in the 
transmembrane domain of the substrate (e.g., TGFα, EGF) 
determine specificity of rhomboid proteases (Urban and 
Freeman 2003); however, it is likely that amino acid resi-
dues in TM helices 5 and 6 of the peptidase domain could 
also account for differences in specificity. Because TM 
helix 5, which tilts its top ~ 35° laterally from the enzyme 
core (Fig. 5D), acts as the substrate gate (Baker et al. 
2007), differences in amino acid residues in TM helix 5 
could govern substrate specificity. However, future studies 
are needed to more thoroughly define the role of the dor-
mant peptidase domain in conferring specificity for targets.
How do iRhoms regulate secretion of EGFR 
ligands and TNFα?
The underlying mechanisms are still emerging, but two 
hypotheses have been proposed based on available data:
ADAM17 hypothesis
iRhoms have been shown to regulate maturation, trafficking, 
and activation of ADAM17, a metalloprotease required for 
ectodomain shedding of EGFR ligands and TNFα (Adrain 
et al. 2012; McIlwain et al. 2012; Maretzky et al. 2013). 
Thus, according to this hypothesis, mice lacking Rhbdf1 or 
Rhbdf2 or both together fail to promote ADAM17 activity, 
thereby leading to significantly reduced secretion of EGFR 
ligands and TNFα following stimulation with phorbol ester 
or LPS. However, genetic evidence deduced from the mouse 
models that we and others have generated argue against this 
hypothesis. First, the necessity of RHBDF2 for ADAM17 
maturation and trafficking raises an obvious question as to 
why Rhbdf2 KO mice do not phenocopy Adam17 KO mice. 
Notably, whereas Adam17 KO results in embryonic or peri-
natal lethality (Veit 2019), Rhbdf2 KO mice are viable and 
fertile. To this end, Issuree et al. (Issuree et al. 2013) sug-
gested that RHBDF1 compensates for the loss of RHBDF2 
in Rhbdf2 KO mice and facilitates ADAM17 maturation and 
trafficking, and hence Rhbdf2 KO mice do not phenocopy 
Adam17 KO mice. Consistent with the Issuree et al. study, 
Li et al. (2015) showed that, whereas Rhbdf1 and Rhbdf2 
single KO mice are viable and fertile, Rhbdf1/Rhbdf2 double 
KO mice phenocopy Adam17 KO mice, exhibiting perinatal 
lethality, open eyelids at birth, and heart valve defects. Li 
et al.’s findings are in direct conflict with the results of a 
previous study by Christova et al. (2013), who found that 
Rhbdf1 single KO mice have multiorgan pathologies, and 
Rhbdf1:Rhbdf2 double KO mice show early embryonic 
lethality. To try to resolve this discrepancy, we found that 
both the Rhbdf1 single KO mice and the Rhbdf1/Rhbdf2 dou-
ble KO mice generated by Li et al. are indeed not null for 
RHBDF1 as they retain residual RHBDF1 functional activity 
(Hosur et al. 2020). This brings into question the notion as 
to whether RHBDF1 compensates for the loss of RHBDF2 
in regulating ADAM17 maturation and trafficking, and the 
association in general between iRhoms and ADAM17 matu-
ration, trafficking, and activation. Second, transcriptome data 
suggest that macrophages (human and mouse) express both 
Rhbdf1 and Rhbdf2 (Fig. 4B). According to the ADAM17 
hypothesis, loss of RHBDF2 is compensated by RHBDF1, 
and vice versa. However, Rhbdf2 KO macrophages show sig-
nificantly reduced stimulated secretion of TNFα (Hosur et al. 
2014; Adrain et al. 2012; McIlwain et al. 2012; Siggs et al. 
2012), even though Rhbdf1 is expressed in Rhbdf2-null mac-
rophages, arguing against the iRhoms-ADAM17 hypothesis. 
Third, Rhbdf2-null mice show reduced stimulated secretion 
of EGFR ligands, including AREG and TGFα, in keratino-
cytes. It has been suggested that loss of RHBDF2 fails to 
promote ADAM17 maturation, trafficking, and activity, lead-
ing to the reduction in stimulated secretion of EGFR ligands. 
Again, according to the ADAM17 hypothesis, RHBDF1, 
which is abundantly expressed in keratinocytes (Fig. 5B), 
compensates for the loss of RHBDF2. However, contrary to 
this prediction, Rhbdf2-null keratinocytes show significantly 
reduced stimulated secretion of EGFR ligands. Lastly, and 
more importantly, this hypothesis does not account for target 
specificity of RHBDF1 and RHBDF2. For instance, GOF 
mutation in Rhbdf2 (Rhbdf2cub), but not in Rhbdf1 (Rhbd-
f1viable), selectively regulates AREG secretion to induce loss-
of-hair and wound healing phenotypes. Therefore, it seems 
unlikely that iRhoms regulate secretion of EGFR ligands and 
TNFα through direct regulation of ADAM17 maturation, 
trafficking, and activation.
Fig. 5  Sequence alignment of the rhomboid peptidase 
domain.  A  Sequence alignment of the peptidase domain of the 
rhomboid family of proteins showing highly conserved catalytic 
serine and histidine residues in transmembrane helix (TMH) 4 and 
TMH6, respectively. Rhomboid proteins lacking the catalytic dyad 
(serine and/or histidine residues) do not show protease activity 
(highlighted residues).  B  Violin plots showing expression of vari-
ous mouse and human genes in keratinocytes. In both mouse (left 
panel) and human (right panel) keratinocytes, Rhbdf1, Rhbdf2, Areg, 
Tgfa,  and  Adam17  are expressed. C  Sequence alignment of mouse 
and human rhomboid dormant peptidase domain with non-similar 
residues between RHBDF1 and RHBDF2 highlighted. D Amino acid 
residues in TMH 5 and 6 that are non-similar between RHBDF1 and 
RHBDF2 in both human and mouse (left panel). The crystal structure 
of the E. coli rhomboid protease GlpG was used to indicate the non-
similar residues in TMH 5 and 6 (right)
◂
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Target trafficking hypothesis
According to this hypothesis, RHBDF1 regulates secretion 
of EGFR ligand TGFα through delivery of pro-TGFα to the 
plasma membrane, where pro-TGFα undergoes ectodomain 
shedding by ADAM17 to release TGFα. In breast cancer 
cell lines, Li J. et al. showed that RHBDF1 is an essential 
component of the protein trafficking machinery involving 
clathrin-coated vesicles (Li et al. 2018). Following stimula-
tion with the G-protein-coupled receptor agonist Sphingo-
sine 1 Phosphate (S1P), RHBDF1 participates in clathrin 
uncoating of vesicles to deliver pro-TGFα to the cell surface. 
Specifically, RHBDF1 interacts with a clathrin-coated vesi-
cle protein auxilin-2 to recruit Heat shock cognate protein 
(HSC70) to the vesicles to initiate clathrin uncoating. Fur-
thermore, siRNA-mediated silencing of RHBDF1 inhibits 
the interaction between HSC70 and auxilin-2, significantly 
reducing TGFα secretion by preventing uncoating of clathrin 
and delivery of pro-TGFα to the plasma membrane for ecto-
domain shedding. Although in vivo validation is required 
to further support the target trafficking hypothesis, these 
findings could help address certain unanswered questions, 
such as the observation that Rhbdf2 KO macrophages dem-
onstrate reduced stimulated secretion of TNFα. According 
to the target trafficking hypothesis, RHBDF2 deficiency 
does not affect ADAM17 activity, but due to target speci-
ficity (RHBDF2 for TNFα), RHBDF2 deficiency in mac-
rophages, regardless of RHBDF1 expression, suppresses 
TNFα secretion.
Concluding remarks
iRhoms are characterized by a cytosolic N-terminal domain, 
a luminal IRHD, and a transmembrane dormant peptidase 
domain. Since the initial discovery in Rhbdf2cub mice that in 
the absence of the cytosolic N-terminal domain, the dormant 
transmembrane peptidase domain of RHBDF2 is sufficient 
to regulate EGFR signaling through secretion of EGFR 
ligand AREG, a substantial amount of literature has revealed 
the biological functions of iRhoms domains. Furthermore, 
the normal development and survival of Rhbdf1viable3 mice 
demonstrates that whereas the N-terminal domain and the 
IRHD are dispensable for viability and fecundity, the loss of 
the transmembrane dormant peptidase domain is associated 
with developmental defects, indicating that the peptidase 
domain is essential and is sufficient to regulate the secre-
tion of diverse EGFR ligands. Although in vitro biochemical 
assays indicate some redundant functions for RHBDF1 and 
RHBDF2 in controlling secretion of various EGFR ligands, 
mouse genetic studies reveal unique signaling pathways and 
distinct client proteins for iRhoms. Additionally, uncover-
ing the pathological role of iRhoms in epithelial cancers, 
inflammation, and skin diseases suggests iRhoms as poten-
tial therapeutic targets. Particularly, since ADAM17 inhibi-
tion to block secretion of EGFR ligands, including AREG, 
is associated with severe adverse effects (Ieguchi and Maru 
2016), identification of selective inhibitors of the dormant 
peptidase domain—although challenging—could lay the 
foundation for the development of more selective and effec-
tive therapeutics targeting iRhoms to abrogate multiple 
pathogenic signaling pathways.
Highlights
• Rhomboid proteases, first discovered in Drosophila, are 
intramembrane serine proteases. Members of the rhom-
boid protein family lacking protease activity are known 
as inactive rhomboids (iRhoms) or pseudoproteases.
• Both spontaneous and genetically engineered mouse 
models of iRhoms have been critical tools to explore the 
molecular and cellular functions of key iRhom protein 
domains—the cytosolic N-terminus, and the transmem-
brane dormant peptidase domain—in development and 
disease.
• The N-terminus and the dormant peptidase domain have 
opposing roles. While the N-terminus negatively regu-
lates EGFR signaling, the dormant peptidase domain 
stimulates EGFR signaling when not suppressed by the 
N-terminus.
• RHBDF1 and RHBDF2 have both discrete and overlap-
ping functions during development. For survival and nor-
mal growth, the dormant peptidase domain of RHBDF1 
is adequate to compensate for the loss of the N-termini 
of iRhoms and for the complete loss of RHBDF2.
• The N-terminal domain and TM helix 1 of RHBDF2 are 
essential for TNFα secretion.
• The iRhom homology domain (IRHD) of RHBDF1 
appears to be dispensable for survival and/or ligand 
secretion, but the role of the IRHD of RHBDF2 is 
unknown.
Outstanding questions
• Rhbdf1  KO mice die of brain hemorrhage and car-
diac fibrosis. What are the physiological substrates of 
RHBDF1 and the underlying signaling pathways that 
maintain brain and heart function? Addressing these 
questions may have implications for treating neurologi-
cal disorders, such as Alzheimer’s and Parkinson’s, as 
well as cardiac abnormalities.
• TM helices 2–6, which harbor the dormant peptidase 
domain, of iRhoms are essential for stimulated secretion 
of EGFR ligands. Which amino acid residues in the dor-
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mant peptidase domain regulate secretion in vivo? These 
findings will help in rational drug design of potential 
novel treatments for cancer and skin diseases.
• iRhoms have overlapping functions only during devel-
opmental stages. Why does RHBDF2 not rescue multio-
rgan pathology, including brain hemorrhage and cardiac 
fibrosis, in Rhbdf1-null mice? Is RHBDF2 not expressed 
in the brain and heart during later stages, i.e., postnatal 
days?
• There is a need to understand tissue-specific regulation 
of EGFR ligand secretion by iRhoms. Mutations in the 
N-terminus (Rhbdf2TOC) or loss of the entire N-terminus 
(Rhbdf2cub) in RHBDF2 enhance AREG secretion to 
cause a hair loss phenotype. However, mutations in the 
N-terminus (Rhbdf1viable) or loss of the entire N-terminus 
(Rhbdf1viable3) in RHBDF1 do not result in a similar phe-
notype.
Note Tissue-specific gene expression data were obtained 
from the  ARCHS4 database, which provides access to gene 
counts from HiSeq 2000, HiSeq 2500, and NextSeq 500 
platforms for human and mouse experiments from GEO 
and SRA (Lachmann et al. 2018). We downloaded expres-
sion files (gene-level) for mouse (mouse_matrix_v10.h5) 
and human ((human_matrix_v10.h5) and selected the sam-
ples with tissue annotation from metadata as macrophages 
(Fig. 4A) and keratinocytes (Fig. 5B).
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